Next, to comprehensively evaluate the in vivo effect of the combination of neratinib with CDK4/6 inhibitor and endocrine therapy in HR+/HER2-low breast cancer, a xenograft mouse model was established with human HR+/HER2-low breast cancer cells. This evidence concerns the gene ERBB2 and breast cancer.